A recent perspective published in eGastroenterology, Professor Wen-Xing Ding and colleagues from The University of Kansas Medical Center highlights emerging evidence that megamitochondria in alcohol-associated liver disease (ALD) may initially function as adaptive metabolic responses rather than merely pathological structures. The article summarizes groundbreaking mechanistic studies linking impaired mitochondrial fission, mtDNA release, cGAS–STING activation, and altered pyrimidine metabolism to ALD progression and liver tumorigenesis. These findings redefine the role of mitochondrial dynamics in chronic liver disease and suggest novel therapeutic opportunities for ALD and hepatocellular carcinoma.

People who undergo bariatric surgery and see substantial weight loss are better able to cope with household tasks such as cleaning, laundry and grocery shopping. The improvements are also sustained over a long time, according to a study at the University of Gothenburg.

Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are disorders associated with dysfunctional lipid metabolism and obesity.  In a recent study, researchers have reviewed and compared the definition, causes, diagnostic methods, and emerging treatments of MASLD and IPFD that could help improve patients’ outcomes. In addition, they shed light on recent advances in artificial intelligence applications and presented personalized therapy integrated with the liver‐pancreas axis, providing novel insights for disease management.

A novel PET imaging approach enables simultaneous visualization of tumor progression and cardiac inflammatory responses during cancer treatment. Using this strategy, researchers demonstrated the effectiveness of a new combination therapy that enhances tumor response while reducing cardiac inflammation. This new paradigm, presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting, offers a more comprehensive assessment of therapeutic impact, supporting more personalized clinical decision‑making.